New brain scan could spot Alzheimer's earlier

NCT ID NCT07580703

Recruiting now Diagnosis Sponsor: Eli Radiopharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a radioactive tracer called [18F]Flortaucipir, used during a PET scan to detect tau protein tangles in the brain—a hallmark of Alzheimer's disease. Researchers will enroll 18 Chinese adults aged 50-85 with normal cognition, mild cognitive impairment, or Alzheimer's to check the tracer's safety, how it moves through the body, and how well it spots disease signs. The goal is to see if this imaging method can help diagnose Alzheimer's more accurately.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]Flortaucipir Injection (a radioactive tracer for PET scans)
What this could lead to: If successful, this could improve early detection of Alzheimer's disease by showing tau protein buildup in the brain.
What could go wrong: This is a very early Phase I study with only 18 participants, so results may not apply broadly. The tracer involves radiation exposure, and its diagnostic accuracy is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AD - ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AD - ALZHEIMER'S DISEASE MCI

Contacts and locations

Locations

Chinese PLA General Hospital
RECRUITING

Beijing, Beijing Municipality, 100853, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.